NeuroTherapia is conducting a phase 2a trial of NTRX-07 in Alzheimer’s
NeuroTherapia, Inc. conducted a 28-day double-blind, randomized phase 2a trial of its oral candidate NTRX-07 in patients with Alzheimer’s disease. The trial enrolled 48 subjects in a 1:1 randomized design at five sites in Hungary, Poland and the Czech Republic…












